Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 22,004 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Female Reproductive System Adnexal Neoplasm, Ovarian Carcinoma, Female Reproductive System Neoplasm, Ovarian Neoplasms, Adnexal Lesion, Ovarian Lesion
Interventions: Transvaginal Ultrasound, Ultrasound Microvessel Imaging; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Interventions: Denikitug, Nivolumab, Ramucirumab, Paclitaxel; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 4
States / cities: Boston, Massachusetts • Albany, New York • New York, New York

Conditions: Breast Cancer, Early-stage Breast Cancer
Interventions: Fasting; Behavioral
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Chronic Pain
Interventions: CBT, Mindfulness, and Movement; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Pulmonary Hypertension, Cardiovascular Diseases
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 7,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Late Life Depression (LLD), Depression - Major Depressive Disorder
Interventions: High-intensity (6 mA) transcranial direct current stimulation (tDCS); Device
Lead sponsor: Andre Russowsky Brunoni; Other
Eligibility: 60 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Sickle Cell Disease
Interventions: Alemtuzumab, low dose total body irradiation, Sirolimus; Drug
Lead sponsor: Robert Nickel; Other
Eligibility: 2 Years to 25 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • New York, New York + 2 more

Conditions: Advanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma A, Locally Advanced Colorectal Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions: Trifluridine and Tipiracil Hydrochloride, Talazoparib Tosylate; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Healthy
Interventions: Cardiac MRI; Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 35 Years to 65 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2030
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Essential Tremor, Upper Extremity Essential Tremor
Interventions: Deep brain stimulation; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 21 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Bipolar Disorder Type I With Mania or Mania With Mixed Features
Interventions: KarXT, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 28
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Culver City, California + 23 more

Conditions: Renal Calculi, Urinary Calculi
Interventions: Break Wave extracorporeal lithotripsy; Device
Lead sponsor: SonoMotion; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 3
States / cities: San Diego, California • San Francisco, California • Seattle, Washington

Conditions: Loneliness
Interventions: Prescribing of community activities; at least 2 hours per week; Behavioral
Lead sponsor: Endeavor Health; Other
Eligibility: 55 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Diabetes Mellitus, Type 1, Diabetes, Type 1 Diabetes, Diabetes Mellitus
Interventions: No intervention; Other
Lead sponsor: T1D Exchange, United States; Other
Eligibility: Not listed
Enrollment: 50,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Renal Cell Carcinoma, Metastatic Biliary Tract Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Biospecimen Collection, Immune Checkpoint Inhibitor; Procedure · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Infant Death, Sudden Infant Death
Interventions: TodaysBaby; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: Female only
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hearing Disorder
Interventions: Electrical extracochlear stimulation; Device
Lead sponsor: Auricle Health Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cardiovascular Diseases (CVD)
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2050
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Pancreas Cancer, Lung Cancer, Renal Cancer, Adrenal Metastases, Prostate Cancer, Liver Metastases, Oligoprogressive Nodal Metastases, Metachronous Nodal Metastases, Synchronous Nodal Metastases, Mesothelioma, Spine Metastases, Brain Metastases, Borderline Resectable Pancreatic Carcinoma
Interventions: MR-guided Linac; Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Fatigue
Interventions: Fisetin followed by Placebo, Placebo followed by Fisetin; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 65 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Aphasia
Interventions: Visual Feedback Training; Behavioral
Lead sponsor: The University of Texas at Dallas; Other
Eligibility: 21 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 3
States / cities: Irvine, California • Columbia, South Carolina • Richardson, Texas

Conditions: Carbohydrate Metabolism
Interventions: CS- Beverage, CS+Fast, CS+Slow; Other
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Ureter Injury
Interventions: filricianine; Drug
Lead sponsor: Intuitive Surgical; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Newport Beach, California • New Haven, Connecticut • Orlando, Florida + 6 more

Conditions: Postpartum, Hypertension, Hypertensive Disorder of Pregnancy
Interventions: 2-Week Home Monitoring, 6-Week Home Monitoring; Diagnostic Test
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming

Integrating Nonpharmacologic Strategies for Pain With Inclusion, Respect, and Equity

CVD/PH and Voice Characteristics

tDCS for Late-Life Depression

Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

Coordinated Reset Deep Brain Stimulation for Essential Tremor

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

Break Wave(TM) Extracorporeal Lithotripter First-in-Human Study

Structured Opportunities for Connection to Improve Aging-related Loneliness

The T1D Exchange Registry

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Get Social Media and Risk-Reduction Training

Evaluation of Cochlear (Promontory) Stimulation During Awake Ear Surgery (TONES Study)

Heart Institute BioRepository (HIBR) for Pediatric Heart Disease

Stereotactic Magnetic Resonance Guided Radiation Therapy

Pilot Study of Fisetin to Improve Fatigue Among Older Adult Cancer Survivors

Neural Bases of Vocal Sensorimotor Impairment in Aphasia

Neural and Metabolic Factors in Carbohydrate Reward

IS-001 Injection in Patients Undergoing Robotic-Assisted Colorectal Surgery

HOPE-BP 2.0: Evaluating the Optimal Duration of Postpartum Remote Blood Pressure Monitoring